Omeprazole and PGC-formulated heparin binding epidermal growth factor normalizes fasting blood glucose and suppresses insulitis in multiple low dose streptozotocin diabetes model. - Wikidata - wikimedia - TriplyDB

Omeprazole and PGC-formulated heparin binding epidermal growth factor normalizes fasting blood glucose and suppresses insulitis in multiple low dose streptozotocin diabetes model.

Omeprazole and PGC-formulated heparin binding epidermal growth factor normalizes fasting blood glucose and suppresses insulitis in multiple low dose streptozotocin diabetes model.

http://www.wikidata.org/entity/Q37238824

about

Neuregulin 1 improves complex 2-mediated mitochondrial respiration in skeletal muscle of healthy and diabetic mice.

P2860

Q41824778-FEC0F4EA-DF61-46A5-88ED-1D813CBFCD0B

P2860

Omeprazole and PGC-formulated heparin binding epidermal growth factor normalizes fasting blood glucose and suppresses insulitis in multiple low dose streptozotocin diabetes model.

http://www.wikidata.org/entity/Q37238824

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@en

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@nl

type

label

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@en

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@nl

prefLabel

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@en

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@nl

P1433

Q37238824-A2FB1B85-6884-4089-965F-83D8B8D12C64

P1476

Q37238824-FAB5A697-4753-4DEC-B0A7-756186E363A4

P2093

Q37238824-14653DD5-39AA-425C-9F78-A08DEF80B5F5

Q37238824-225FC066-D5D1-4309-898F-F684B83292C6

Q37238824-2C309C93-ED4C-422C-BB59-18918B236853

Q37238824-5005B416-65BB-4053-95A4-4EEEA417B4CA

Q37238824-60AD49E5-EE52-410E-9809-77B7F08B6B2B

Q37238824-E74F6B6A-8685-4514-917D-F10679313DB2

P2860

Q37238824-04DE9949-9EB1-4508-A2A5-DDC3289A5FB5

Q37238824-0DF0A8D3-8E71-485B-85DB-7424C641A146

Q37238824-16AEDBD2-6FD8-40EF-B0D0-163F81B4D54D

Q37238824-176BBBC9-CB15-4D1B-9BAC-C13FDAA796F3

Q37238824-1B6609F7-27AC-4C30-AF48-2CE0BFE7D336

Q37238824-31E77290-A172-499F-B9EE-263F5F5F622A

Q37238824-5180BE28-3CD3-4FB2-8E96-730801743E91

Q37238824-5372792B-2FEE-456E-B93F-EB47A25BC976

Q37238824-550B9050-FECC-4280-8608-0AF0D9D86E89

Q37238824-64F66D68-2D01-43C3-AA54-BE72698BF4EA

P304

Q37238824-4FCFEE89-F523-4664-A342-6DD5762A317B

P31

Q37238824-C45CFB0A-DA56-4BA1-90D4-06E615043C9E

P356

Q37238824-129A5F70-FA55-411B-B772-68B5CABD4FE5

P433

Q37238824-F570D6B5-338B-4210-AF72-CC94A2B6165A

P478

Q37238824-8DFBAAFB-A7C0-433C-9EDB-7A27C3F42A42

P577

Q37238824-F695A776-F7F3-457E-8BFA-9913DF835EC8

P5875

Q37238824-A003FA48-895C-44C3-8C3D-6F0210215FFD

P698

Q37238824-7ED2EDD9-5E53-487A-AF24-CE98874D7D58

P932

Q37238824-C0B736BA-0095-4954-A00B-7B773F00F3EC

P356

S11095-013-1112-6

P1433

Pharmaceutical Research

P1476

Omeprazole and PGC-formulated ...... streptozotocin diabetes model.

@en

P2093

Akiko Nishimoto-Ashfield

http://www.w3.org/2001/XMLSchema#string

Alexander V Lyubimov

http://www.w3.org/2001/XMLSchema#string

Aryamitra A Banerjee

http://www.w3.org/2001/XMLSchema#string

Elijah M Bolotin

http://www.w3.org/2001/XMLSchema#string

Gerardo M Castillo

http://www.w3.org/2001/XMLSchema#string

Jennifer A Landolfi

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality study of 18 000 patients treated with omeprazole.

Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose.

Islet transplantation for brittle type 1 diabetes: the UIC protocol.

Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin.

Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.

Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia.

Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.

Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Functional selectivity of EGF family peptide growth factors: implications for cancer.

P304

2843-2854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-013-1112-6

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

241694211

http://www.w3.org/2001/XMLSchema#string

P698

23793991

http://www.w3.org/2001/XMLSchema#string

P932

3800254

http://www.w3.org/2001/XMLSchema#string